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Abstract
Background PALB2 has recently been identified as a breast
cancer susceptibility gene. PALB2 mutations are rare causes of
hereditary breast cancer but may be important in countries such
as Finland where a founder mutation is present. We sought to
estimate the contribution of PALB2 mutations to the burden of
breast cancer in French Canadians from Quebec.
Methods We screened all coding exons of PALB2 in a sample
of 50 French-Canadian women diagnosed with either early-
onset breast cancer or familial breast cancer at a single Montreal
hospital. The genetic variants identified in this sample were then
studied in 356 additional women with breast cancer diagnosed
before age 50 and in 6,448 newborn controls.
Results We identified a single protein-truncating mutation in
PALB2 (c.2323 C>T, resulting in Q775X) in 1 of the 50 high-
risk women. This variant was present in 2 of 356 breast cancer
cases and in none of 6,440 newborn French-Canadian controls
(P = 0.003). We also identified two novel new non-synonymous
single nucleotide polymorphisms in exon 4 of PALB2 (c.5038
A>G [I76V] and c.5156 G>T [G115V]). G115V was found in 1
of 356 cases and in 15 of 6,442 controls (P = 0.6). The I76V
variant was not identified in either the extended case series or
the controls.
Conclusion We have identified a novel truncating mutation in
PALB2. The mutation was found in approximately 0.5% of
unselected French-Canadian women with early-onset breast
cancer and appears to have a single origin. Although mutations
are infrequent, PALB2 can be added to the list of breast cancer
susceptibility genes for which founder mutations have been
identified in the French-Canadian population.
bp = base pairs; CI = confidence interval; DCIS = ductal carcinoma in situ; ER = estrogen receptor; HER2-neu = human epidermal growth factor 
receptor 2; MLPA = multiplex ligation-dependent probe amplification; OR = odds ratio; PALB2 = partner and localizer of BRCA2; PCR = polymerase 
chain reaction; PR = progesterone receptor.Breast Cancer Research    Vol 9 No 6    Foulkes et al.
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Introduction
Approximately 3% to 5% of breast cancer is estimated to be
due to a dominantly inherited gene, and two breast cancer
genes, BRCA1 and BRCA2, account for approximately 85%
of families with four or more cases of breast and ovarian can-
cer [1]. Soon after these genes were discovered, it became
apparent that specific founder mutations in these genes were
present in different ethnic groups [2,3], including individuals of
French-Canadian descent [4]. Five founder mutations account
for 75% to 85% of all BRCA1/2 mutations in the French-
Canadian population of Quebec [5,6]. However, for approxi-
mately one half of strongly hereditary breast cancer families,
no BRCA1/2 mutation has been identified and other genes
are believed to be important.
Many of the known hereditary breast cancer genes such as
BRCA1,  BRCA2, CHEK2,  ATM, and FANCJ/BRIP1  work
together in a DNA repair pathway [7], raising the possibility
that other genes in this pathway also predispose to breast
cancer. PALB2 ('partner and localizer of BRCA2') was
recently identified to play an important role in facilitating the
function of BRCA2; nearly 50% of BRCA2 is associated with
PALB2 and more than 50% of PALB2 forms a complex with
BRCA2 [8]. Association of BRCA2 with PALB2 appears to be
essential for BRCA2 anchorage to nuclear structures and for
its function in homologous recombination and double-strand
break repair [8].
Studies including clinical samples from the UK [9,10], The
Netherlands [11], Finland [12], and Canada [13] have con-
firmed that, like BRCA2 [14,15], PALB2 is both a breast can-
cer susceptibility gene and a Fanconi anemia gene. Disease-
associated variants in PALB2 are rare in the UK population,
with only approximately 1% of familial breast cancer being
attributable to mutations in this gene, whereas 1% of all breast
cancer in Finland is due to a single mutation (1592delT) in
PALB2 [12].
We performed PALB2 mutation analysis in a series of unre-
lated French-Canadian women with breast cancer diagnosed
at a single hospital in Montreal, Quebec, with the aim of iden-
tifying possible founder mutations and determining their con-
tribution to breast cancer. We then estimated the population
prevalence of each variant identified in a series of DNA sam-
ples from 6,448 newborns from Quebec City [16].
Materials and methods
Patients with breast cancer
All women were recruited from Hotel Dieu Hospital in Montreal
and were seen in the breast clinic between October 2003 and
May 2007. Women were selected for this study on the basis
of (a) a diagnosis of first primary breast cancer under the age
of 50 or (b) a diagnosis of breast cancer between the ages of
50 and 65 with at least one other case of breast or ovarian
cancer in first- or second-degree relatives diagnosed at any
age and (c) French-Canadian ancestry (all four grandparents).
A total of 600 women were identified. Lymphocyte DNA
extracted from the 600 French-Canadian women with breast
cancer was undertaken using standard methods. All women
had consented to participate in studies to identify potential
breast cancer genes which had been subject to local ethical
review. All women in the series had been previously tested for
five French-Canadian founder mutations (BRCA1: 4666C>T
and 2953delGTAinsC; BRCA2: 8765delAG, 6085C>T, and
3398delAAAG) [5]. Fifty women were selected for the pre-
screen on the basis of their age and/or family history of breast
and ovarian cancer. The median age of this group of women
was 47.1 years (range 24 to 65 years). Three hundred fifty-six
women were diagnosed with breast cancer under the age of
50 (median age 43 years, range 24 to 49 years). These two
groups were analyzed for PALB2  mutations, as described
below. The collection of cases was approved by appropriate
institutional ethics review boards.
Newborn controls
The population prevalence of each variant identified was esti-
mated using a series of 6,448 newborn controls and a previ-
ously described and validated pooling strategy [16]. As
reported previously [16], newborn cord blood leftovers were
collected at the Hôpital St-François-d'Assise maternity unit
Table 1
Primers and conditions used for the newborn DNA population prevalence study
Mutation Primers (5' to 3') Wild-type allele conditions Mutated allele conditions
Q775X ACCAGTGGAGCCCTTTGAGTC-common primer
GCCTGAACTGTCGAATTG-wild-type allele
GCCTGAACTGTCGAATTA-mutated allele
Annealing temperature of 59°C for 35 
cycles
Annealing temperature of 59°C for 36 
cycles
I76V TAGTCGCCCTGGTGAAATTAG-common primer
CTCAGAACCTAAAAATAAAA-wild-type allele
CTCAGAACCTAAAAATAAAG-mutated allele
Annealing temperature of 51°C for 36 
cycles
Annealing temperature of 55°C for 38 
cycles
G115V TACTTGAGCCAAGGGGGAAAA-common
CTGTTCTTTGTATAGGTAATC-wild-type allele
CTGTTCTTTGTATAGGTAATA-mutated allele
Annealing temperature of 53°C for 35 
cycles
Annealing temperature of 53°C for 39 
cyclesAvailable online http://breast-cancer-research.com/content/9/6/R83
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(Quebec City) between 1996 and 2003 and were made anon-
ymous and unlinked. DNA was purified from each sample and
quantified, and pools of eight samples were prepared into bar-
coded 96-well working plates using a QIAGEN BioRobot
3000 (Qiagen GmbH, Hilden, Germany). The final concentra-
tion of an individual genome in a pool was 7.5 ng/μL (on aver-
age), and 5 μL of each pool (or 38 ng of each genome) was
used for genotyping. Genotyping was performed by allele-spe-
cific oligonucleotide polymerase chain reaction (PCR) in bar-
coded 96-well microplates (Axygen Scientific, Inc., Union City,
CA, USA) in a final volume of 25 μL containing 5 μL of DNA
pools and 20 μL of PCR premix (1.5 μL 10× buffer [Qiagen
GmbH], 200 μM of each deoxynucleoside triphosphate, 7.5
pmol of each primer, and 0.375 units of HotStarTaq DNA
polymerase [Qiagen GmbH]) using a previously described
quasi-homogeneous methodology [16] that is highly repro-
ducible, robust, and affordable. Table 1 describes the primers
and PCR conditions used for each mutation tested. Raw gen-
otyping results were analyzed by in-house software in VC++
that determined genotypes and produced a result file with all
pools. Individual samples from positive pools were tested sep-
arately using the same assay to confirm the presence of muta-
tions. In all, 6,440 results were obtained for 6,448 samples for
a call rate of greater than 99%. All positive pools were con-
firmed by individual sample analysis. The newborn study was
approved by institutional ethics review boards in Quebec City
and Montreal.
PALB2 sequencing
The PALB2 genomic sequence was obtained from the Univer-
sity of California at Santa Cruz Genome Browser, accession
number NM_024675. Intronic primers were designed using
Primer3 software (Whitehead Institute for Biomedical
Research, Cambridge, MA, USA). Due to their large size,
exons 4 and 5 were amplified in 4 and 2 amplicons, respec-
tively; all primer sequences and annealing temperatures are
listed in the online supplementary table from reference 13. We
performed whole genome amplification of the 50 cases cho-
sen for full sequencing (Repli-G mini kit; Qiagen GmbH) and
confirmed all new variants identified by re-sequencing stock
DNA in both directions. The PCRs were carried out in a vol-
ume of 50 μL, as previously described [13]. Sequence data
were analyzed using the Lasergene SeqMan Pro sequence
analysis software by DNASTAR, Inc. (Madison, WI, USA) and
Chromas 2.31 from Technelysium Pty Ltd. (Helensvale,
Australia).
PALB2 exon deletion analysis
Multiplex ligation-dependent probe amplification (MLPA) was
performed using the FANCD2-PALB2 kit (P057) from MRC-
Holland b.v. (Amsterdam, The Netherlands) in accordance
with the manufacturer's protocol. The MLPA assay covers the
PALB2 exons, and in exon 1, one pair of probes covers 30
bases 5' of the ATG start site. The samples were run and ana-
lyzed on an ABI Prism 3100 (Applied Biosystems, Foster City,
CA, USA) using fragment analysis tools.
Testing for the new PALB2 variants in the under-50-years 
series
We developed a specific assay to look for the three novel var-
iants we identified in the first phase of the study. The amplifi-
cation refractory mutation system was employed for screening
of the I76V and Q775X variants detected by direct sequenc-
ing in the first 50 French-Canadian cases with breast cancer.
The inner and outer primer pairs used for genotyping of the
I76V variant were 5'-TTTTCCTCCTCAGAACCTAAAAATA-
CAA-3', 5'-TTTGATGTGTAACTTGTCATAAACACAGAC-3',
5'-CAGTGACCTTACTACTC ACAGCCTAAAA-3', and 5'-
CAGTGACCTTACTACTCACAGCCTAAAA-3' at an anneal-
ing temperature of 52°C and for genotyping of the Q775X var-
iant were 5'-ACTCAGTCTGTCTTGCCAGTGATACTACAC-
3', 5'-GCTGGGCTGCCTGAACTGTCGAAGTA-3', 5'-TCT-
TAGGTACTACTCCAGC CTTTGGCCC-3', and 5'-TCCT-
GGCATGTGTTTCTACAGAGCTGAT-3' at an annealing
temperature of 62°C. A restriction fragment length polymor-
phism assay was used for genotyping of the G115V variant.
The primer pairs of 5'-TGCCTGAATGAAATGTCACTGAT-
TCTT TC-3' and 5'-GGTGTCATCTGTTCTTTGTATAGGT-
cAT-3' were used for DNA amplification. Because there was
no restriction enzyme cutting DNA at the site of mutation, the
latter primer contained one mismatch nucleotide for producing
a site identified by BtsCI enzyme. The length of the amplified
DNA fragment was 296 base pairs (bp), and the enzyme cut
the wild-type allele and produced two fragments of 273 and
23 bp whereas the mutated allele remained intact. All putative
mutations were confirmed by sequencing.
PALB2 haplotyping
For each of the three families that carry the Q775X mutation,
we genotyped one individual for four microsatellite markers by
PCR using an S35-dATP label. The markers used were
D16S403, D16S481, and D16S3130 proximal to PALB2,
and D16S417 distal to PALB2. (Primer sequences and PCR
conditions are available in The Genome Database [17].)
Pathology
The breast tumors from the three women carrying the identi-
fied truncating variant (Q775X) were re-analyzed by the study
pathologist (TAB) and stained for estrogen receptor (ER), pro-
gesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2-neu). Briefly, immunohistochemistry was
performed using the NexES immunostainer (Ventana Medical
Systems, Inc., Tuscon, AZ, USA). Formalin-fixed paraffin-
embedded tissue of selected blocks from the three cases was
stained by hematoxylin and eosin to confirm diagnosis. Primary
antibodies for ER and PR (pre-diluted; Ventana Medical Sys-
tems, Inc.) (clone SP1 and IE2; rabbit monoclonal) and HER2
(Cell Signaling Technology, Inc., Danvers, MA, USA) (1:100)
(clone 29D8; rabbit monoclonal) were used. ImmunostainingBreast Cancer Research    Vol 9 No 6    Foulkes et al.
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was performed on 4-μm silane-coated slides (Sigma-Aldrich,
St. Louis, MO, USA), which were dried overnight at 37°C and
then dewaxed, rehydrated, and boiled (microwave) in EDTA
(ethylenediaminetetraacetic acid) (pH 7.0) for antigen
retrieval. Slides were incubated for 32 minutes at 37°C using
the primary antibodies listed above. Diaminobenzidine was
used as a chromogen, and slides were counterstained with
hematoxylin before mounting. Negative controls were obtained
by omitting the specific primary antibodies. Protein expression
was assessed using a four-tiered system (0, negative; 1, weak;
2, moderate; and 3, high expression).
Results
In the first phase of the study, we sequenced PALB2 in its
entirety in 50 French-Canadian breast cancer patients
selected on the basis of age of diagnosis or family history.
Deletion analysis, using MLPA, was performed on 43 of the 50
samples. Sequence analysis identified one clearly pathogenic
mutation, c.2323C>T (starting from the first ATG, or c.2523
C>T using GenBank nomenclature), resulting in protein trun-
cation (Q775X). The proband carrying the Q775X mutation
was diagnosed with invasive ductal breast cancer at age 54.
We also identified two novel single nucleotide polymorphisms,
c.5038 ATA>GTA (I76V) and c. 5156 GGA>GTA (G115V),
both in exon 4 (Table 2). We also observed several single
nucleotide polymorphisms, each of which has been previously
identified in normal controls [10,13]. No deletions or duplica-
tions were identified by MLPA.
In the second phase of the study, we analyzed 356 unrelated
French-Canadian women diagnosed with invasive ductal
breast cancer under age 50 for the three variants. We identi-
fied two carriers of the Q775X mutation (0.56%, 95% confi-
dence interval [CI] 0.06% to 2.0%). The mutation was
confirmed in both cases by re-sequencing of DNA from a new
blood sample. This mutation is clearly pathogenic as it trun-
cates the protein, and other truncating mutations occurring
both before and after this amino acid are known to be capable
of causing breast cancer. Notably, this mutation occurs before
the WD-40 repeats, which are common protein-protein inter-
acting motifs, and therefore, even if the Q775X generates a
stable protein, the binding site for at least some of the PALB2
partners will have been lost. Nevertheless, the N-terminal puta-
tive coiled-coil domain remains intact, so it is possible in this
scenario that some protein-protein interactions involving
PALB2 will remain unaffected by this mutation.
We then genotyped four polymorphic microsatellite markers
(D16S403, D16S481, and D16S3130 proximal to PALB2,
and D16S417 distal to PALB2) and found that mutation carri-
ers from the three families share a common allele at each
locus. This is consistent with the possibility that Q775X is a
founder mutation that arose on a common ancestral chromo-
some in the French-Canadian population, although further
segregation data will be required to confirm this.
The two other novel variants, I76V and G115V, were studied
in the entire series of cases. G115V was found in 1 of 356
early-onset cases, but I76V was not identified in any case. We
then analyzed DNA from 6,448 newborns from Quebec City
for the three variants identified in the first phase of the study.
No carrier of the Q775X truncating variant was identified in
these newborns, and the difference in frequencies between
cases and controls reached statistical significance (P  =
0.003). The other two PALB2 variants were not associated
with breast cancer; G115V was identified in 15 of 6,442 new-
borns (odds ratio [OR] = 1.2; 95% CI, 0.02 to 7.9; P = 0.99),
and I76V was not found in any control (Table 2).
The pedigrees of the three families in which the index case car-
ried a Q775X mutation are shown in Figure 1 (Figure 1:
P28031; Figure 2: P31030; and Figure 3: P26007). All
women had a family history of breast cancer, and the BRC-
APRO [18] scores for the probands were 0.03, 0.74, and
0.007, respectively. In two families, P28031 (Figure 1) and
P26007 (Figure 3), it was possible to obtain samples from
other affected family members and demonstrate segregation
of the mutation. The tumors from the three women with trun-
cating PALB2 mutations were studied in greater detail (Table
3). P28031 was diagnosed with a 1.5-cm grade 2 infiltrating
ductal breast cancer at the age of 54. The lymph nodes were
not involved by tumor. The tumor was ER+, PR+, and HER2-
neu-. There was associated ductal carcinoma in situ (DCIS)
(cribriform subtype, grade I/III). P31030 was initially diag-
Table 2
PALB2 mutations identified in early-onset French-Canadian women with breast cancer and their frequencies in newborn controls
PALB2 variant Frequency in cases (percentage) Frequency in controls (percentage) P value
Q775X 2/356 (0.56) 0/6,440 (0) 0.0027
I76V 0/356 (0) 0/6,442 (0) -
G115V 1/356 (0.28) 15/6,442 (0.12) 0.99
All variants 3/356 15/6,442 0.065Available online http://breast-cancer-research.com/content/9/6/R83
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nosed with DCIS (micropapillary and solid types, grade II/III) at
age 49 in the left breast. The DCIS showed moderate expres-
sion of HER2 and was ER-moderate and PR-weak. The patient
subsequently underwent a modified radical mastectomy for
the right breast for a diagnosis of invasive ductal carcinoma
grade 3 (maximum diameter 0.7 cm) with pagetoid spread and
lymphovascular invasion. DCIS was also present (micropapil-
lary and clinging types, grade III/III). Three out of 16 axillary
lymph nodes showed metastatic carcinoma. The invasive
tumor was ER- and PR-. However, HER2-neu showed only
weak expression. P26007 was diagnosed with an infiltrating
ductal breast cancer at age 36. Measured clinically, the tumor
was 3 cm. She was treated with neoadjuvant chemotherapy,
and the post-treatment breast tissue showed no evidence of
cancer in either the breast or in 14 lymph nodes. The pre-treat-
ment biopsy showed invasive ductal carcinoma with medullary
features, grade 3. Immunohistochemistry showed the tumor to
be ER-, PR-, and HER2-neu-.
Discussion
We have identified the PALB2  mutation Q775X to be a
founder mutation for breast cancer in the French-Canadian
population. To date, this mutation has been identified only in
affected women of French-Canadian descent. The Q775X
mutation appears to account for approximately 0.5% of breast
cancer diagnosed in French-Canadian women under the age
of 50. By contrast, five founder mutations in BRCA1/2 [5]
account for approximately 4.3% of such women and
CHEK2:1100delC is found in approximately 0.7% of these
cases (P Ghadirian, A Robidoux, R Royer, P Zhang, S Zhang,
E Fafard, M Costa, F Rousseau, G Martin, C Potvin et al., man-
uscript submitted; S Zhang, CM Phelan, P Zhang, F Rous-
Figure 1
Pedigree of the P28031 family, whose index case carried a Q775X mutation Pedigree of the P28031 family, whose index case carried a Q775X mutation. The proband was diagnosed with breast cancer at age 54. She has 
female relatives on both sides of the family who have been diagnosed with breast cancer (n = 2 on paternal side, n = 4 on maternal side), and the 
mutation was shown to segregate on the maternal side, with a 46-year-old affected cousin also found to be a carrier. Remarkably, there appear to be 
five relatives, including her mother, who have been diagnosed with colorectal cancer. Plus sign indicates Q775X mutation carrier. PSU, primary site 
unknown.
Figure 2
Pedigree of the P31030 family, whose index case carried a Q775X mutation Pedigree of the P31030 family, whose index case carried a Q775X mutation. The proband was diagnosed with breast cancer at age 49. She 
reports two relatives diagnosed with breast cancer on her mother's side. She reports that her mother was diagnosed with colorectal cancer at age 
32. Plus sign indicates Q775X mutation carrier. PSU, primary site unknown.Breast Cancer Research    Vol 9 No 6    Foulkes et al.
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seau, P Ghadirian, A Robidoux, W Foulkes, N Hamel, D
McReady, M Trudeau et al., manuscript submitted). The novel
PALB2 exon 4 missense variants I76V and G115V were both
identified in the initial screening series, but I76V was not found
subsequently. Although I76V seems to be rare, it is a relatively
conservative change (Grantham score = 29; SIFT [sorting
intolerant from tolerant] prediction = tolerated). G115V was
found in both cases and controls, but the similar frequency and
bioinformatic analyses (data not shown) indicate that this vari-
ant is highly unlikely to be associated with an increased risk for
breast cancer. Moreover, exon 4 sequences are not essential
for DNA repair associated with PALB2 function.
One of the strengths of this study is that the 356 cases stud-
ied in the second phase were not selected for family history. In
addition, we were able to analyze a very large population-
based sample of 6,448 newborns as a control group and thus
can be sure that Q775X is not present at an appreciable fre-
quency in the population (upper limit of 95% CI = 0.057%, or
1/1,745), using the Sign test with exact 95% CI.
Figure 3
Pedigree of the P26007 family, whose index case carried a Q775X mutation Pedigree of the P26007 family, whose index case carried a Q775X mutation. The proband was diagnosed with breast cancer at age 36. She does 
not report any breast tumors on her father's side of the family, but her mother (who was also found to carry the mutation) was diagnosed with breast 
cancer at age 62. There are also cases of leukemia, colon cancer, and thyroid cancer reported on this side of the family. Plus sign indicates Q775X 
mutation carrier.
Table 3
Pathology findings in the breast specimens from three Q775X mutation carriers
Feature P28031 P31010a P26007
Histological type IDC Left breast DCIS only Right breast IDC IDC with medullary features
Size (cm) (invasive) 1.5 N/A 0.7 3.0b
BRE histological grade (IDC) 2 N/A 3 3
Associated DCIS Cribriform, grade 1 Clinging micropapillary,
grade 2
Micropapillary and clinging,
grade 3
Not present
Nodal involvement 0/1 (sentinel) N/A 3/16 0/14c
Estrogen receptor +++ (>90%) + (20%) - -
Progesterone receptor +++ (>90%) ++ (50%) - -
HER2-neu expression - ++ - (+ in 10% CIS) + (10% of cells)
aPatient initially had excisional biopsy followed by modified radical mastectomy.
bBased on clinical measurement: the patient had neoadjuvant chemotherapy (doxorubicin and cyclophosphamide).
cFollowing neoadjuvant chemotherapy.
Key for immunohistochemical staining: +++, strongly positive; ++, moderately positive; +, weakly positive; -, negative.
BRE, Bloom-Richardson-Ellis; CIS, carcinoma in situ; DCIS, ductal carcinoma in situ; HER2-neu, human epidermal growth factor receptor 2; IDC, 
infiltrating ductal breast cancer; N/A, not applicable.Available online http://breast-cancer-research.com/content/9/6/R83
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PALB2 is a protein of approximately 130 kDa which interacts
with BRCA2 and is a major determinant of the nuclear locali-
zation of BRCA2 [8]. Notably, it has recently been found to be
a breast cancer susceptibility gene [10,12] and is a cause of
Fanconi anemia, subtype N [9,11]. Until now, eight distinct
truncating mutations have been associated with an increased
risk for breast cancer (I76fs, L531fs, G796X, T841fs, A995fs,
W1038X, N1039fs, and Y1183X) [9,10,12,13]. L531fs
(c.1592delT) is a founder mutation in Finland but so far has not
been seen outside of Finland. W1038X has been found in two
separate families, and both N1039fs and Y1183X have been
seen three times. These eight families were all ascertained in
the UK but other details of their geographical origins have not
been provided. The possibility of a link between these muta-
tions and a defined subpopulation of the UK has not been
excluded.
Previously, we [13] and others [12] showed that most breast
tumors arising in PALB2 mutation carriers are ER+, PR+, and
HER2-, like both BRCA2-related and sporadic breast cancer.
The findings in the three PALB2 mutation carriers reported
here (Table 3) suggest that these prior observations may not
be universal; two of the three invasive tumors were ER- and
one of these was HER2+. Interestingly, one tumor had a med-
ullary phenotype (on a pre-treatment biopsy), which is much
more commonly a feature of BRCA1- than BRCA2-related
breast cancer, although both tend to feature a continuous
pushing margin [19].
This is the fifth study of the role of PALB2 in breast cancer; the
findings are summarized in Table 4. Overall, it appears that
PALB2 mutations are responsible for 1% to 2% of strongly
familial breast cancer, but in Finland (and possibly in other
founder populations), PALB2 mutations may account for up to
1% of all breast cancer. Deleterious PALB2  alleles are
extremely rare in the general population, and only in Finland
have any variants been found in individuals outside the setting
of familial breast cancer. The OR for breast cancer in associa-
tion with a truncating PALB2 mutation cannot easily be deter-
mined as the numbers of mutation carriers in each study are
small, but the two studies [9,12] in which it has been calcu-
lated (using very different methods) found ORs of 2.3 and 3.9,
respectively. A recent study from our group reported on one
Quebec family of Scottish descent in which seven breast
tumors occurred in three women, perhaps suggesting an
increased penetrance [13]. Here, two of the three families
were moderately suggestive of hereditary breast cancer and it
appears that PALB2 generally behaves as a low- to moderate-
penetrance breast cancer susceptibility gene. In this study,
one of the three families reported five cases of colorectal
cancer. In Figure 1, it can be seen that the mutation is present
on the side of the family with colorectal cancer. All three fami-
lies have at least one reported case. Notably, there are no
reported cases of ovarian cancer. The possibility that PALB2
predisposes to colorectal cancer is worthy of further
investigation.
Table 4
PALB2 mutation studies in breast cancer
Cases Carriers/total probands 
studied
Controls Carriers/total probands 
studied
Odds ratio (95% confidence 
interval; P value)
Unselected breast cancer 
(Finland)a [12]
18/1,918 (0.9%) Finnish Red Cross 
blood donorsb
6/2,501 (0.2%) 3.91 (1.5–12.1; 0.002)c
Familial breast cancerd 
(Finland) [12]
3/113 (2.7%) - 6/2,501 (0.2%) 11.1 (1.8–52; 0.006)c
Familial breast cancere 
(UK) [10]
10/923 (1.1%) Female 
breast cancer only 9/908 
(1.0%)
1958 Birth Cohort 
collection, all aged 48
0/1,084 (0%) 2.3 (1.4–3.9; 0.0025)
<50 years: 3.0 (1.4–5.5, NS)
>50 years: 1.9 (0.8–3.7, 
0.35)
Strongly familial breast 
cancer (Canada) [13]
1/68f (1.5%) - - -
Breast cancer diagnosed 
in French-Canadian 
women <50 years of ageg 
(Quebec) (the present 
study)
2/356 (0.56%) Newborns, Quebec 
City, 1996–2003
0/6,440 (0%) -(3.4–∞, 0.0027)
aMean age 57.7 years (range 23 to 95 years).
bMean age 42.0 years (range 18 to 65 years).
cRecalculated from the original data.
dSequenced and negative for BRCA1, BRCA2, CHEK2, and TP53. Sixty-five were strongly familial, and 48 were moderately strong, with at least 2 
cases of breast and/or ovarian cancer in first- or second-degree relatives.
eScreening started with 96 BRCA1/2- families. Thirty-five other genes have been screened in this series. The familial case sequenced was the 
affected proband (male or female) from a family with at least 3 cases of breast cancer diagnosed at any age. All probands were sequenced for 
BRCA1/2 and were also negative for large deletions. 'Non-UK ethnic groups' were excluded. The median age of the probands was 49 years.
fCarrier individual was of Scottish descent. All cases were sequence-negative for BRCA1/2.
gMedian age 43 years (range 23 to 49 years).
NS: Not stated.Breast Cancer Research    Vol 9 No 6    Foulkes et al.
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It is difficult to estimate the penetrance for genes in the class
of PALB2. This is because the allele frequencies of the vari-
ants of the controls are too low to generate a robust estimate
of the relative risk. (In more than 6,000 controls in our study,
the Q775X allele was not found.) One might better estimate
the penetrance by observing the families of cases identified to
carry a PALB2 mutation, identified through the study of unse-
lected cases. However (given the mutation prevalence of
0.5% in early-onset cases in this study), to generate a pedi-
gree sample of sufficient size for analysis, it would be neces-
sary to genotype many thousands of cases. In the French
Canadian population of Quebec, founder mutations have been
identified in BRCA1, BRCA2, and now PALB2. However, the
full clinical relevance of PALB2 mutations is as yet uncertain.
For this reason, genetic counseling solely on the basis of
PALB2 mutation status will pose significant challenges, and
widespread clinical testing for PALB2 mutations is unlikely to
enter the clinical arena at the current time.
Conclusion
We have identified a novel truncating mutation in PALB2
which appears to be a founder mutation in French Canadians.
The mutation was found in approximately 0.5% of unselected
French-Canadian women with early-onset breast cancer. No
mutation carriers were identified in DNA from more than 6,000
newborn controls. PALB2 can be added to the list of breast
cancer susceptibility genes for which founder mutations have
been identified in the French Canadian population.
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